SLC5A2 and hydrops fetalis: As per a recent meta-analysis of 15 randomized trials involving 20,241 patients, the SGLT2 inhibitors significantly reduced the all-cause mortality, composite of cardiovascular mortality, heart failure (HF) hospitalizations and urgent visits for HF among patients with HF in all following subgroups: male, female, age < 65, age ≥ 65, race - Black and White, estimated glomerular filtration rate (eGFR) <60, eGFR ≥60, New York Heart Association (NYHA) class II, NYHA ≥III, and HF with preserved ejection fraction9.